2019 C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

April 2019 | 83 pages | ID: 2FB713B702EEN
VPAResearch

Abstracts

The global clinical trial report- “2019 C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials Study” provides complete list of trials completed, ongoing and planned for C1 Esterase Inhibitor (C1-INH) Deficiency. It presents in-depth analysis of C1 Esterase Inhibitor (C1-INH) Deficiency clinical trials across markets and companies. The research work is for providing complete understanding into trends in C1 Esterase Inhibitor (C1-INH) Deficiency.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the C1 Esterase Inhibitor (C1-INH) Deficiency clinical trials by-

• Current Trial Status
• Type of the trial
• Sponsor Type
• Enrollment Trends
• Region
• Countries
• Trial Phase

The report also identifies the potential drug candidates under development for treatment of C1 Esterase Inhibitor (C1-INH) Deficiency

The research work is prepared through extensive and continuous research on C1 Esterase Inhibitor (C1-INH) Deficiency trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:

• All major trials from 2010 to 2019 and planned trials are included in the report scope.
• Drug candidates currently being researched for administering C1 Esterase Inhibitor (C1-INH) Deficiency patients are identified
• The report includes panorama of C1 Esterase Inhibitor (C1-INH) Deficiency clinical trials across the globe
• Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
• Companies and universities focusing on C1 Esterase Inhibitor (C1-INH) Deficiency clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
• Average Enrollment number, insights into enrollment trends, company wise enrollment are included
• Both interventional and observational studies are analyzed
• News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
  2.2.1 C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials by Region
  2.2.2 Average Enrollment of C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials
  2.2.3 Companies participating in Trials
  2.2.4 Drugs under Study for C1 Esterase Inhibitor (C1-INH) Deficiency Treatment, 2019

3. REGION WISE C1 ESTERASE INHIBITOR (C1-INH) DEFICIENCY CLINICAL TRIALS

3.1 Asia Pacific C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials by Country
3.2 Europe C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials by Country
3.3 North America C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials by Country
3.4 Middle East and Africa C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials by Country
3.5 South and Central America C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials by Country

4. C1 ESTERASE INHIBITOR (C1-INH) DEFICIENCY CLINICAL TRIAL TRENDS

4.1 Start Year wise C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials
4.2 Phase wise C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials
4.3 Trial Status wise C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials
4.4 Trial Type wise C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials

5. C1 ESTERASE INHIBITOR (C1-INH) DEFICIENCY AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in C1 Esterase Inhibitor (C1-INH) Deficiency Trials by Year
5.2 Average Enrollment in C1 Esterase Inhibitor (C1-INH) Deficiency Trials by Phase
5.3 Average Enrollment in C1 Esterase Inhibitor (C1-INH) Deficiency Trials by Status
5.4 Average Enrollment in C1 Esterase Inhibitor (C1-INH) Deficiency Trials by Type of Trial

6. COMPANIES PARTICIPATING IN C1 ESTERASE INHIBITOR (C1-INH) DEFICIENCY CLINICAL TRIALS

6.1 C1 Esterase Inhibitor (C1-INH) Deficiency Trials by Sponsor Type
6.2 C1 Esterase Inhibitor (C1-INH) Deficiency Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 C1 Esterase Inhibitor (C1-INH) Deficiency Trials- Phase
7.2 C1 Esterase Inhibitor (C1-INH) Deficiency Trials- Phase
7.3 C1 Esterase Inhibitor (C1-INH) Deficiency Trials- Phase
7.4 C1 Esterase Inhibitor (C1-INH) Deficiency Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials and Enrolment
Figure 5: Europe – Country wise C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials and Enrolment
Figure 7: North America – Country wise C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials and Enrolment
Figure 9: C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials by Phase
Figure 10: C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials by Trial Status
Figure 11: C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials by Type
Figure 12: C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials by Sponsor Type
Figure 13: C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials by Leading Sponsors
Figure 14: C1 Esterase Inhibitor (C1-INH) Deficiency Average Enrollment by Phase
Figure 15: C1 Esterase Inhibitor (C1-INH) Deficiency Average Enrollment by Trial Status
Figure 16: C1 Esterase Inhibitor (C1-INH) Deficiency Average Enrollment by Type
Figure 17: C1 Esterase Inhibitor (C1-INH) Deficiency- Average Enrolment by Type of Sponsors
Figure 18: C1 Esterase Inhibitor (C1-INH) Deficiency- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials and Enrolment
Table 5: Europe – Country wise C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials and Enrolment
Table 7: North America – Country wise C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials and Enrolment
Table 8: South and Central America – Country wise C1 Esterase Inhibitor (C1-INH) Deficiency Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: C1 Esterase Inhibitor (C1-INH) Deficiency Average Enrollment by Phase
Table 15: C1 Esterase Inhibitor (C1-INH) Deficiency Average Enrollment by Trial Status
Table 16: C1 Esterase Inhibitor (C1-INH) Deficiency Average Enrollment by Type
Table 17: C1 Esterase Inhibitor (C1-INH) Deficiency- Average Enrolment by Type of Sponsors
Table 18: C1 Esterase Inhibitor (C1-INH) Deficiency- Enrolment by Leading Sponsors